The panel is meeting and currently reviewing data to update the Guidance based on the US FDA approval of ledipasvir/sofosbuvir. The updated Guidance will be posted in early December.
The panel is meeting and currently reviewing data to update the Guidance based on the US FDA approval of ledipasvir/sofosbuvir. The updated Guidance will be posted in early December.